January 2010 - Vivo Biosciences is happy to announce that it has signed a co-marketing agreement with Southern Research. It will promote/market Vivo's new 3D HuBiogel assay platform to enhance its oncology drug screening and preclinical pharmaceutical services. High-value human 3D mini-tumors (monotypic & heterotypic) and angiogenesis assay systems offer an advanced/robust DD pipeline. They are cost-effective and complementary to HTS assays and animal xenograft models.

September 2009 - Birmingham, AL – September 28, 2009 – Dr. Raj K. Singh, President and Chief Scientific Officer of Vivo Biosciences, will be presenting a talk at the upcoming Drug Discovery Partnerships: Filling the Pipeline meeting in Boston, MA on Friday, May 30, 2009. Additionally, Vivo Biosciences will have an exhibition booth at the meeting which is organized by Opal Events. The title of Dr. Singh’s talk is, “New In Vitro Preclinical Drug Discovery Platform Collaborations: Addressing Needs with 3D Mini-Tumor Bioassay Systems.” PDF

July 2009 - Vivo Biosciences is pleased to announce a new SBIR grant awarded by NCI to develop novel dignostic antibodies for prostate cancer patients

May 2009 - Vivo is selected by NIH-ACT to present its 3D HuBiogel technology at Life Sciences VC Forum, San Jose, CA on June 25, 2009. This one-day event, organised by LARTA, highlights NIH-SBIR supported innovative technologies and VC funding opprtunities.

May 2009 - Vivo is happy to announce that it will be exhibiting at the 2009 International BIO conference in Atlanta, Georgia (Booth# 2933, May 18-21). Please stop by to explore R&D collaboration and partnership opportunities in the area of oncology, drug toxicity and patient therapy profiling.